Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05083169 · ClinicalTrials.gov registry record · Phase 3
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 587
- Enrollment target
- 20
- Study locations
NCT05083169 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 587 participants, roughly in line with the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target. The trial reports 20 study locations across 15 states.
The verdict
NCT05083169, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 587 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Dexamethasone
- DRUG Daratumumab
- DRUG Pomalidomide
- DRUG Bortezomib
Study Locations (20)
California
- City of Hope - Duarte
- Stanford University Medical Center - Stanford
Michigan
- Henry Ford Hospital - Detroit
- Henry Ford Health System - Southfield
Pennsylvania
- West Penn Hospital - Pittsburgh
- University of Pittsburgh Medical Center - Pittsburgh
Tennessee
- Baptist Cancer Center - Memphis
- Vanderbilt Ingram Cancer Center - Nashville
Other
- Hospital Aleman - Buenos Aires
- Hospital Italiano de Buenos Aires - Buenos Aires
Alabama
- University of Alabama Birmingham - Birmingham
Connecticut
- Yale University - New Haven
Georgia
- Emory University Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 587 participants |
| Start Date | 2021-10-14 |
| Est. Completion | 2028-12-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05083169
The ClinicalTrials.gov registry entry for NCT05083169 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 587 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Teclistamab is the first listed.
NCT05083169 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Michigan, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05083169 about?
NCT05083169 is a clinical study titled "A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).
What is the current status of trial NCT05083169?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 587 participants. The study started on 2021-10-14. Estimated completion is 2028-12-08.
What conditions does trial NCT05083169 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05083169?
The interventions under investigation include: Teclistamab (DRUG), Dexamethasone (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT05083169?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05083169 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.